Titles and Legends to Supplemental Figures
Supplemental Figure 1 Cytotoxic effect of NSC697923 on NB cells. (a) NGP, NB-19 and CHLA-255 cells were treated with the indicated concentrations of NSC697923 for 24 hrs and then cell morphology was captured using optical microscope. (b) NGP, NB-19 and CHLA-255 cells were first incubated with the indicated concentrations of NSC697923 for 24 hrs, stained by propidium iodide (PI) without fixing and then analyzed by flow cytometry. PI positive cells were shown by percentage. Data from (a) and (b) are representative of three independent experiments.
Supplemental Figure 2 Cytotoxic effect of NSC697923 on the chemoresistant NB cell line LA-N-6. (a) LA-N-6 cells were treated with indicated concentrations of NSC697923, Dox or VP16 for 24 hrs and then cell morphology was captured using optical microscope. (b) LA-N-6 cells were incubated with indicated concentrations of NSC697923 and grown in RPMI 1640 media for 2 weeks. The colonies produced were then fixed, stained with crystal violet dye, and photographed. Data from (a) and (b) are representative of three independent experiments.
Supplemental References
1. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-8.
2. Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 1983;35:359-67.
3. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998;58:5396-405.
4. Van Roy N, Jauch A, Van Gele M, Laureys G, Versteeg R, De Paepe A, et al. Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines. Cancer Genet Cytogenet 1997;97:135-42.
5. Sadée W, Yu VC, Richards ML, Preis PN, Schwab MR, Brodsky FM, et al. Expression of neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma cell line. Cancer Res 1987;47:5207-12.
6. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 1992;7:127-33.
7. Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J. p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol 2001;158:2067-77.
8. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91:355-8.
9. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, et al. COSMIC 2005. Br J Cancer 2006;94:318-22.
10. Nakamura Y, Ozaki T, Niizuma H, Ohira M, Kamijo T, Nakagawara A. Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line. Biochem Biophys Res Commun 2007;354:892-8.
11. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001;61:6185-93.
12. Goto H, Yang B, Petersen D, Pepper KA, Alfaro PA, Kohn DB, et al. Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines. Mol Cancer Ther 2003,2:911-7.